{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T00:15:23Z","timestamp":1790727323454,"version":"4.1.0"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2012,12,4]],"date-time":"2012-12-04T00:00:00Z","timestamp":1354579200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Eur J Nucl Med Mol Imaging"],"published-print":{"date-parts":[[2013,2]]},"DOI":"10.1007\/s00259-012-2291-9","type":"journal-article","created":{"date-parts":[[2012,12,3]],"date-time":"2012-12-03T20:47:56Z","timestamp":1354567676000},"page":"394-402","source":"Crossref","is-referenced-by-count":88,"title":["Regional distribution and kinetics of [18F]fluciclovine (anti-[18F]FACBC), a tracer of amino acid transport, in subjects with primary prostate cancer"],"prefix":"10.1007","volume":"40","author":[{"given":"Jens","family":"S\u00f6rensen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rikard","family":"Owenius","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle","family":"Lax","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Johansson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2012,12,4]]},"reference":[{"key":"2291_CR1","unstructured":"National Cancer Institute. Surveillance Epidemiology and End Results Program. Cancer of the Prostate Statistics. 2010."},{"key":"2291_CR2","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1016\/S0959-8049(96)00492-3","volume":"33","author":"RJ Black","year":"1997","unstructured":"Black RJ, Bray F, Ferlay J, Parkin DM. Cancer incidence and mortality in the European Union: cancer registry data and estimates of national incidence for 1990. Eur J Cancer. 1997;33:1075\u2013107.","journal-title":"Eur J Cancer"},{"issue":"Suppl 1","key":"2291_CR3","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1046\/j.1464-410X.2000.00592.x","volume":"86","author":"MR Engelbrecht","year":"2000","unstructured":"Engelbrecht MR, Barentsz JO, Jager GJ, van der Graaf M, Heerschap A, Sedelaar JP, et al. Prostate cancer staging using imaging. BJU Int. 2000;86 Suppl 1:123\u201334.","journal-title":"BJU Int"},{"key":"2291_CR4","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.2967\/jnumed.108.050658","volume":"49","author":"AB Apolo","year":"2008","unstructured":"Apolo AB, Pandit-Taskar N, Morris MJ. Novel tracers and their development for the imaging of metastatic prostate cancer. J Nucl Med. 2008;49:2031\u201341.","journal-title":"J Nucl Med"},{"key":"2291_CR5","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1038\/nrurol.2009.81","volume":"6","author":"H Jadvar","year":"2009","unstructured":"Jadvar H. Molecular imaging of prostate cancer with 18F-fluorodeoxyglucose PET. Nat Rev Urol. 2009;6:317\u201323. doi: 10.1038\/nrurol.2009.81 .","journal-title":"Nat Rev Urol"},{"key":"2291_CR6","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1148\/radiol.09090413","volume":"254","author":"M Beheshti","year":"2010","unstructured":"Beheshti M, Imamovic L, Broinger G, Vali R, Waldenberger P, Stoiber F, et al. 18F choline PET\/CT in the preoperative staging of prostate cancer in patients with intermediate or high risk of extracapsular disease: a prospective study of 130 patients. Radiology. 2010;254:925\u201333. doi: 10.1148\/radiol.09090413 .","journal-title":"Radiology"},{"key":"2291_CR7","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.eururo.2010.09.004","volume":"59","author":"M Picchio","year":"2011","unstructured":"Picchio M, Briganti A, Fanti S, Heidenreich A, Krause BJ, Messa C, et al. The role of choline positron emission tomography\/computed tomography in the management of patients with prostate-specific antigen progression after radical treatment of prostate cancer. Eur Urol. 2011;59:51\u201360. doi: 10.1016\/j.eururo.2010.09.004 .","journal-title":"Eur Urol"},{"key":"2291_CR8","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1016\/j.urology.2005.11.044","volume":"67","author":"G Sandblom","year":"2006","unstructured":"Sandblom G, S\u00f6rensen J, Lundin N, H\u00e4ggman M, Malmstr\u00f6m P-U. Positron emission tomography with C11-acetate for tumor detection and localization in patients with prostate-specific antigen relapse after radical prostatectomy. Urology. 2006;67:996\u20131000.","journal-title":"Urology"},{"key":"2291_CR9","doi-asserted-by":"crossref","first-page":"2513","DOI":"10.1200\/JCO.2005.03.5279","volume":"24","author":"S Wachter","year":"2006","unstructured":"Wachter S, Tomek S, Kurtaran A, Wachter-Gerstner N, Djavan B, Becherer A, et al. 11C-acetate positron emission tomography imaging and image fusion with computed tomography and magnetic resonance imaging in patients with recurrent prostate cancer. J Clin Oncol. 2006;24:2513\u20139. doi: 10.1200\/JCO.2005.03.5279 .","journal-title":"J Clin Oncol"},{"key":"2291_CR10","first-page":"287","volume":"47","author":"E Even-Sapir","year":"2006","unstructured":"Even-Sapir E, Metser U, Mishani E, Lievshitz G, Lerman H, Leibovitch I. The detection of bone metastases in patients with high-risk prostate cancer: 99mTc-MDP planar bone scintigraphy, single- and multi-field-of-view SPECT, 18F-fluoride PET, and 18F-fluoride PET\/CT. J Nucl Med. 2006;47:287\u201397.","journal-title":"J Nucl Med"},{"key":"2291_CR11","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.radonc.2009.08.010","volume":"93","author":"J Sepp\u00e4l\u00e4","year":"2009","unstructured":"Sepp\u00e4l\u00e4 J, Sepp\u00e4nen M, Arponen E, Lindholm P, Minn H. Carbon-11 acetate PET\/CT based dose escalated IMRT in prostate cancer. Radiother Oncol. 2009;93:234\u201340.","journal-title":"Radiother Oncol"},{"key":"2291_CR12","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1097\/RLU.0b013e31819e51e3","volume":"34","author":"AB Jani","year":"2009","unstructured":"Jani AB, Fox TH, Whitaker D, Schuster DM. Case study of anti-1-amino-3-F-18 fluorocyclobutane-1-carboxylic acid (anti-[F-18] FACBC) to guide prostate cancer radiotherapy target design. Clin Nucl Med. 2009;34:279\u201384.","journal-title":"Clin Nucl Med"},{"key":"2291_CR13","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1097\/RLU.0b013e318208f140","volume":"36","author":"EY Yu","year":"2011","unstructured":"Yu EY, Muzi M, Hackenbracht JA, Rezvani BB, Link JM, Montgomery RB, et al. C11-acetate and F-18FDG PET for men with prostate cancer bone metastases: relative findings and response to therapy. Clin Nucl Med. 2011;36:192\u20138. doi: 10.1097\/RLU.0b013e318208f140 .","journal-title":"Clin Nucl Med"},{"key":"2291_CR14","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1007\/s00066-010-2122-5","volume":"186","author":"M Pinkawa","year":"2010","unstructured":"Pinkawa M, Holy R, Piroth MD, Klotz J, Nussen S, Krohn T, et al. Intensity-modulated radiotherapy for prostate cancer implementing molecular imaging with 18F-choline PET-CT to define a simultaneous integrated boost. Strahlenther Onkol. 2010;186:600\u20136. doi: 10.1007\/s00066-010-2122-5 .","journal-title":"Strahlenther Onkol"},{"key":"2291_CR15","doi-asserted-by":"crossref","first-page":"6093","DOI":"10.1158\/1078-0432.CCR-10-1357","volume":"16","author":"GS Meirelles","year":"2010","unstructured":"Meirelles GS, Schoder H, Ravizzini GC, Gonen M, Fox JJ, Humm J, et al. Prognostic value of baseline [18F] fluorodeoxyglucose positron emission tomography and 99mTc-MDP bone scan in progressing metastatic prostate cancer. Clin Cancer Res. 2010;16:6093\u20139. doi: 10.1158\/1078-0432.CCR-10-1357 .","journal-title":"Clin Cancer Res"},{"key":"2291_CR16","first-page":"56","volume":"48","author":"DM Schuster","year":"2007","unstructured":"Schuster DM, Votaw JR, Nieh PT, Yu W, Nye JA, Master V, et al. Initial experience with the radiotracer anti-1-amino-3-18F-fluorocyclobutane-1-carboxylic acid with PET\/CT in prostate carcinoma. J Nucl Med. 2007;48:56\u201363.","journal-title":"J Nucl Med"},{"key":"2291_CR17","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.2967\/jnumed.107.040097","volume":"48","author":"JA Nye","year":"2007","unstructured":"Nye JA, Schuster DM, Yu W, Camp VM, Goodman MM, Votaw JR. Biodistribution and radiation dosimetry of the synthetic nonmetabolized amino acid analogue anti-18F-FACBC in humans. J Nucl Med. 2007;48:1017\u201320.","journal-title":"J Nucl Med"},{"key":"2291_CR18","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1007\/s12149-011-0477-z","volume":"25","author":"Y Asano","year":"2011","unstructured":"Asano Y, Inoue Y, Ikeda Y, Kikuchi K, Hara T, Taguchi C, et al. Phase I clinical study of NMK36: a new PET tracer with the synthetic amino acid analogue anti-[18F]FACBC. Ann Nucl Med. 2011;25:414\u20138. doi: 10.1007\/s12149-011-0477-z .","journal-title":"Ann Nucl Med"},{"key":"2291_CR19","doi-asserted-by":"crossref","first-page":"2380","DOI":"10.1111\/j.1349-7006.2008.00969.x","volume":"99","author":"K Kaira","year":"2008","unstructured":"Kaira K, Oriuchi N, Imai H, Shimizu K, Yanagitani N, Sunaga N, et al. l-type amino acid transporter 1 and CD98 expression in primary and metastatic sites of human neoplasms. Cancer Sci. 2008;99:2380\u20136. doi: 10.1111\/j.1349-7006.2008.00969.x .","journal-title":"Cancer Sci"},{"key":"2291_CR20","unstructured":"McParland BJ, Lax M, Axelsson J, Wall A, Johansson S, Sorensen J. The biodistribution and internal radiation dosimetry of [18F]GE-148 in healthy adult volunteers. Eur J Nucl Med Mol Imaging. 2010;37 (Suppl 2):S287"},{"key":"2291_CR21","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1016\/S0969-8043(03)00029-0","volume":"58","author":"J McConathy","year":"2003","unstructured":"McConathy J, Voll RJ, Yu W, Crowe RJ, Goodman MM. Improved synthesis of anti-[18F]FACBC: improved preparation of labeling precursor and automated radiosynthesis. Appl Radiat Isot. 2003;58:657\u201366.","journal-title":"Appl Radiat Isot"},{"key":"2291_CR22","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1097\/00004728-198406000-00028","volume":"8","author":"RM Kessler","year":"1984","unstructured":"Kessler RM, Ellis Jr JR, Eden M. Analysis of emission tomographic scan data: limitations imposed by resolution and background. J Comput Assist Tomogr. 1984;8:514\u201322.","journal-title":"J Comput Assist Tomogr"},{"key":"2291_CR23","first-page":"167","volume-title":"Nuclear medicine: diagnosis and therapy","author":"R Carson","year":"1996","unstructured":"Carson R. Mathematical modeling and compartmental analysis. In: Harbert J, Eckelman WC, Neumann R, editors. Nuclear medicine: diagnosis and therapy. New York: Thieme Medical Publishers; 1996. p. 167\u201394."},{"key":"2291_CR24","first-page":"1069","volume":"30","author":"E Meyer","year":"1989","unstructured":"Meyer E. Simultaneous correction for tracer arrival delay and dispersion in CBF measurements by the H215O autoradiographic method and dynamic PET. J Nucl Med. 1989;30:1069\u201378.","journal-title":"J Nucl Med"},{"key":"2291_CR25","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1109\/TAC.1974.1100705","volume":"19","author":"H Akaike","year":"1974","unstructured":"Akaike H. A new look at the statistical model identification. IEEE Trans Autom Control. 1974;19:716\u201323. doi: 10.1109\/TAC.1974.1100705 .","journal-title":"IEEE Trans Autom Control"},{"key":"2291_CR26","doi-asserted-by":"crossref","first-page":"206","DOI":"10.2967\/jnumed.107.044453","volume":"49","author":"C Schiepers","year":"2008","unstructured":"Schiepers C, Hoh CK, Nuyts J, Seltzer M, Wu C, Huang SC, et al. 1-11C-acetate kinetics of prostate cancer. J Nucl Med. 2008;49:206\u201315. doi: 10.2967\/jnumed.107.044453 .","journal-title":"J Nucl Med"},{"key":"2291_CR27","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1097\/JTO.0b013e31815e6d6b","volume":"3","author":"T Berghmans","year":"2008","unstructured":"Berghmans T, Dusart M, Paesmans M, Hossein-Foucher C, Buvat I, Castaigne C, et al. Primary tumor standardized uptake value (SUVmax) measured on fluorodeoxyglucose positron emission tomography (FDG-PET) is of prognostic value for survival in non-small cell lung cancer (NSCLC): a systematic review and meta-analysis (MA) by the European Lung Cancer Working Party for the IASLC Lung Cancer Staging Project. J Thorac Oncol. 2008;3:6\u201312.","journal-title":"J Thorac Oncol"},{"key":"2291_CR28","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1016\/j.ijrobp.2010.11.050","volume":"82","author":"KA Higgins","year":"2012","unstructured":"Higgins KA, Hoang JK, Roach MC, Chino J, Yoo DS, Turkington TG, et al. Analysis of pretreatment FDG-PET SUV parameters in head-and-neck cancer: tumor SUV(mean) has superior prognostic value. Int J Radiat Oncol Biol Phys. 2012;82:548\u201353. doi: 10.1016\/j.ijrobp.2010.11.050 .","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2291_CR29","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1200\/JCO.2007.14.3628","volume":"26","author":"JK Hoang","year":"2008","unstructured":"Hoang JK, Hoagland LF, Coleman RE, Coan AD, Herndon JE, Patz EF. Prognostic value of fluorine-18 fluorodeoxyglucose positron emission tomography imaging in patients with advanced-stage non-small-cell lung carcinoma. J Clin Oncol. 2008;26:1459\u201364. doi: 10.1200\/jco.2007.14.3628 .","journal-title":"J Clin Oncol"}],"container-title":["European Journal of Nuclear Medicine and Molecular Imaging"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-012-2291-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00259-012-2291-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-012-2291-9","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,2]],"date-time":"2024-05-02T12:14:51Z","timestamp":1714652091000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00259-012-2291-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,12,4]]},"references-count":29,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2013,2]]}},"alternative-id":["2291"],"URL":"https:\/\/doi.org\/10.1007\/s00259-012-2291-9","relation":{},"ISSN":["1619-7070","1619-7089"],"issn-type":[{"value":"1619-7070","type":"print"},{"value":"1619-7089","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,12,4]]}}}